<p>This episode examines CAR T-cell therapy’s early successes, broader promise, and emerging risks, as the FDA considers reports of occasional secondary cancers.</p>
<p>A full transcript of this episode is available at nejm.org/doi/full/10.1056/NEJMp2400701.</p>

This episode examines CAR T-cell therapy’s early successes, broader promise, and emerging risks, as the FDA considers reports of occasional secondary cancers. A full transcript of this episode is available at nejm.org/doi/full/10.1056/NEJMp2400701.

CAR T-Cells and Safety Signals

From the New England Journal of Medicine, welcome to “Intention to Treat,” a podcast exploring the most complicated, perplexing, and fascinating issues facing medicine today. From groundbreaking research, to clinical advances, to personal stories from doctors and their patients, we give you a behind-the-scenes look at discoveries that are changing medical practice and provide you with the knowledge to thrive on the front lines of health care.

Share CAR T-Cells and Safety Signals

Sign up to save your podcasts

CAR T-Cells and Safety Signals

CAR T-Cells and Safety Signals

More shows like Intention to Treat

Health Report - Full program podcast

TED Talks Daily

NEJM Interviews

NEJM Journal Watch Podcasts: Clinical Conversations

Luke's ENGLISH Podcast - Learn British English with Luke Thompson

NEJM This Week

CHEST Journal Podcasts

JAMA Clinical Reviews

Hidden Brain

The Daily

Leadership Conversations

Curbside Consults

Americast

The Ezra Klein Show

NEJM AI Grand Rounds

Not Otherwise Specified